

03-14-02

#3 Cup 1617  
CASE 4-20017D  
3/20/02

RECEIVED

MAR 20 2002

TECH CENTER 1600/2900

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 041586259 US  
Express Mail Label Number

March 13, 2002  
Date of Deposit



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1617

ULRICH POSANSKI

APPLICATION NO: 10/040,842

FILED: JANUARY 7, 2002

FOR: PHARMACEUTICAL COMPOSITIONS FOR SPARINGLY SOLUBLE  
THERAPEUTIC AGENTS

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:


Applicant wishes to make of record the references cited on attached forms PTO-1449 (8 sheets) which are copied from parent applications 08/578,527 and 09/524,965. Since the references are available in said parent applications, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 forms.

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027

Date: March 13, 2002

  
Gabriel Lopez  
Attorney for Applicant  
Reg. No. 28,440  
(908) 522-6933

Encl.: PTO-1449 (8 sheets)

FORM PTO-1449  
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

4-20017/A/PC

SERIAL NO.

08/578,527

APPLICANT

Posanski

FILING DATE


1-5-96

TECH CENTER 1600/2900

MAR 20 2002  
GROUP

RECEIVED

INFORMATION DISCLOSURE CITATION



(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	CLASS	SUBCLASS	TRANSLATION
SW	AA	0274870	7-20-88	Europe		
SW	AB	9300891	12-93	PCT		
SW	AC	2228198	8-22-90	Great Britain		
SW	AD	1132518	11-6-68	Great Britain		
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					

EXAMINER

SW

DATE CONSIDERED

1/9/03

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.